FEATURED APPLICATION CONTENT

• Antibody Structure Modeling With Discovery Studio

  Improving the understanding of critical properties of antibodies as early as possible in development and formulation will impact speed and total cost to market. When 3D structures are not available from X-RAY or NMR, 3D in silico models generated are the solution.

• Tackling NTDs At Collaborations Pharmaceuticals - Streamlining Drug Repurposing

  The diversity of the pathogens implicated in NTDs, the relative complexity of their life cycles and their poor tractability in the lab have resulted in a lack of potential therapeutic targets and candidates. By repurposing existing high throughput screening (HTS) data for Ebola and Chagas Disease to create machine learning models which could screen libraries for potential active compounds, especially compounds previously approved by the US FDA for other diseases, they were able to provide safe and efficacious treatments for those who need them most.

• Integrated Predictive Sciences Solutions To Accelerate Drug Discovery And Innovation

  Learn how having the right predictive sciences capabilities integrated into R&D work flows delivers a scientific decision support environment that reduces time and expense, improves quality, enhances collaboration and accelerates innovation in bringing new drugs to market.

• Implementing An Integrated Quality System To Support Business Growth

  A multinational pharmaceutical company with world-wide commercial operations provides contract manufacturing, product development and clinical services to third-party customers. Geographically-dispersed and disconnected business units demanded virtual collaborations that were not easy to support, and many processes throughout the company were manual and disconnected, hindering productivity and collaboration. The company implemented a solution to enable them to deliver high quality, compliant products in an efficient manner.

• Liquid-Liquid Mixing Without Vortex Formation

  This application note describes liquid-liquid homogenization conditions which meet these requirements at various filling levels in four types of mixers.

• Trends In Single-Use Mixing Technologies

  Here we present an overview of the current mixing technology landscape driven by the need for versatile biomanufacturing platforms with increased productivity.

• In Vitro Dissolution Methodologies For Amorphous Solid Dispersions

  With the availability of so many types of in vitro dissolution tests, how do you determine which one will be most effective in predicting in vivo performance of your BCS II or IV drug product?

• Capture Of Histidine-Tagged Molecules Using Biacore His Capture Kit

  Find recommendations for immobilization of histidine-tagged molecules (ligands) by capture to an anti-histidine antibody covalently coupled to a sensor chip surface.

• Combining Ambr 15 Cell Culture With Octet Titer Measurements

  This platform is an analytical instrument that can easily be implemented in cell line development labs to facilitate rapid determination of product yield.

• Quality by Design (QbD) for Adeno-Associated Virus (AAV)

  CMC is but one obstacle to gene therapy regulatory approval. Here we review a framework for QbD assessment of AAV products within the Chemistry Manufacturing and Controls documentation.

• Local Treatment Of Non-Small Cell Lung Cancer With A Spray-Dried Bevacizumab Formulation

  Local delivery of biotherapeutics to the lung holds great promise for treatment of lung diseases, but development of physically stable, biologically active dry powder formulations of large molecules for inhalation has remained a challenge.

• Analytical Power Tools Open Upstream Bioprocessing Bottlenecks

  Clone selection is a significant upstream bottleneck slowing bench-to-bedside development progress for new mAbbased therapeutics. With mAb-based product development addressing diseases of such massive financial and societal implications, researchers using analytical power tools can reach their goals faster and shorten the bench-to-bedside development path, benefitting both patients and the bottom line.